The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Open accessAbstract
An engineered cancer immunotherapy using a collagen-binding domain enhances efficacy and reduces adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Importantly, combination treatment with CPI and IL-2 resulted in complete elimination of tumors in a considerable number of animals (9 of 13) bearing orthotopic breast cancer [137].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“immune checkpoint inhibitors (antibodies) including anti-CTLA4 and anti-PD-L1 plus IL-2 were conjugated to the collagen-binding domain of the blood protein von willebrand factor (VWF) A3 domain to reduce side effects.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This formulation allowed drug targets to bind to the tumor stroma to exert their effects locally and gained a promising efficacy and safety profile compared to the unconjugated molecules tested in several mouse models.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Danhier, F., Féron, O., & Véronique Préat, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,891
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S. F., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Ricard-Blum, S. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004978 · Cited by 2,305
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867
Alsaab, H. O., Sau, S., Alzhrani, R. M., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,750
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature reviews. Immunology · doi:10.1038/nri3156 · Cited by 1,743
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Collagen density promotes mammary tumor initiation and progression
Provenzano, P. P., Inman, D. R., Eliceiri, K. W., Knittel, J. G., Yan, L., Rueden, C., White, J. G., & Keely, P. J. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-11 · Cited by 1,394
Rosenberg, S. A. (1994) · JAMA · doi:10.1001/jama.1994.03510360033032 · Cited by 1,100
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“As a consequence, CBD-CPI treatment enhanced effector (CD62L−CD44+) CD8+ T cell–to-Treg ratios within the tumor, a predictor of therapeutic efficacy (32), compared to equidosed unmodified CPI and PBS treatments (Fig.”
BackgroundWhy are tumour blood vessels abnormal and why is it important to know?
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611
Interstitial Flow and Its Effects in Soft Tissues
Swartz, M. A., & Fleury, M. E. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.151850 · Cited by 606
Self-citationRole of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 568
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 561
Kufe, D. W. (2012) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 452
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. A. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 433
Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381
Mach, J. P., Buchegger, F., Forni, M., Ritschard, J., Berche, C., Lumbroso, J.-D., Schreyer, M., Girardet, C., Accolla, R. S., & Carrel, S. (1981) · Immunology Today · doi:10.1016/0167-5699(81)90011-6 · Cited by 376
Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P., Khuri, F. R., Ahmed, R., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31043 · Cited by 337
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Hadrup, S. R., Donia, M., & Straten, P. T. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0127-6 · Cited by 318
Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002) · Blood · doi:10.1182/blood.v99.5.1659 · Cited by 294
Glycoprotein VI–dependent and –independent pathways of thrombus formation in vivo
Dubois, C., Panicot‐Dubois, L., Merrill‐Skoloff, G., Furie, B., & Furie, B. C. (2006) · Blood · doi:10.1182/blood-2005-09-3687 · Cited by 236
Immune Checkpoint Blockade in Cancer Therapy
Allison, J. P. (2015) · JAMA · doi:10.1001/jama.2015.11929 · Cited by 213
Extracellular Matrix Proteins in Hemostasis and ThrombosisPreprint
Bergmeier, W., & Hynes, R. O. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005132 · Cited by 193
The role of blood platelets in tumor angiogenesis
Sabrkhany, S., Griffioen, A. W., & Egbrink, M. G. A. O. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.12.001 · Cited by 181
Zhu, E. F., Gai, S. A., Opel, C. F., Kwan, B. H., Surana, R., Mihm, M. C., Kauke, M. J., Moynihan, K. D., Angelini, A., Williams, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.004 · Cited by 179
Zhou, Z.-H., Ji, C., Xiao, H., Zhao, H., Cui, Y., & Bian, X. (2017) · Journal of Cancer · doi:10.7150/jca.18466 · Cited by 179
Targeting fibroblast activation protein in cancer ndash Prospects and caveats
Šedo, A. (2018) · Frontiers in bioscience · doi:10.2741/4682 · Cited by 166
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 156
Self-citationLavergne, J. M., Juhan-Vague, I., Obert, B., Cherel, G., Meyer, D., Girma, J.-P., Ribba, A., & Ferreira, I. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616142 · Cited by 136
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 91
Thrombosis and von Willebrand Factor
Shahidi, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_122 · Cited by 88
Multiplex three-dimensional optical mapping of tumor immune microenvironment
Lee, S. S.-Y., Bindokas, V. P., & Kron, S. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-16987-x · Cited by 57
Self-citationA collagen‐binding EGFR single‐chain Fv antibody fragment for the targeted cancer therapy
Liang, H., Li, X., Chen, B., Wang, B., Zhao, Y., Zhuang, Y., Shen, H., Zhang, Z., & Dai, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.029 · Cited by 54
A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix
Liang, H., Li, X., Wang, B., Chen, B., Zhao, Y., Sun, J., Zhuang, Y., Shi, J., Shen, H., Zhang, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep18205 · Cited by 50
Ballmer-Weber, B. K., Dummer, R., Küng, E., Burg, G., & Ballmer, P. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.16 · Cited by 49
Addi, C., Murschel, F., & Crescenzo, G. D. (2016) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2016.0280 · Cited by 47
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Ishihara, J., Ishihara, A., Potin, L., Hosseinchi, P., Fukunaga, K., Damo, M., Gajewski, T. F., Swartz, M. A., & Hubbell, J. A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0091 · Cited by 45
Self-citation
Cited by
Sorted by citations
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Importantly, combination treatment with CPI and IL-2 resulted in complete elimination of tumors in a considerable number of animals (9 of 13) bearing orthotopic breast cancer [137].”
BackgroundComprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 691
Metadata
- Authors
- Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., Raczy, M. M., Gray, L. T., Mansurov, A., Katsumata, K., Fukayama, M., Kron, S. J., Swartz, M. A., & Hubbell, J. A.
- Affiliations
- University of Chicago (US)
- Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, IL 60637, USA.
- The University of Tokyo (JP)
- Department of Pathology, University of Tokyo, 113-8655 Tokyo, Japan.
- Corresponding author
- Ishihara, Jun
- Ishihara, Ako
- Katsumata, Kiyomitsu
- Hubbell, Jeffrey A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-04-10
- Volume
- 11
- Issue
- 487
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6541444
- OpenAlex
- W2939112943
- Cited by
- 190
- References
- 49
- Citations by year
- 2026: 20 · 2025: 16 · 2024: 20 · 2023: 30 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 12
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Cancer Institute (CA199663)
- National Institute of Biomedical Imaging and Bioengineering (EB022636)
- European Research Commission grant (Cytrix)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- cancer immunotherapy, cytokine therapy, interleukin-2, antibody-drug conjugates, breast cancer, tumor targeting, combination therapy, orthotopic tumor model
- MeSH terms
- Protein Domains, Animals, Antibodies, Neoplasm, Collagen, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Immunity, Immunotherapy, Injections, Intravenous, Interleukin-2, Melanoma, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Cytokines, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, CD8-Positive T-Lymphocytes, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
